Free Trial
NASDAQ:ILMN

Illumina (ILMN) Stock Price, News & Analysis

$116.09
-1.91 (-1.62%)
(As of 07/12/2024 ET)
Today's Range
$115.42
$119.94
50-Day Range
$101.05
$118.98
52-Week Range
$89.00
$195.64
Volume
1.61 million shs
Average Volume
2.18 million shs
Market Capitalization
$18.49 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$158.57

Illumina MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
36.6% Upside
$158.57 Price Target
Short Interest
Healthy
3.15% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
0.69mentions of Illumina in the last 14 days
Based on 19 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
183.67%
From $0.98 to $2.78 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.85 out of 5 stars

Medical Sector

26th out of 917 stocks

Analytical Instruments Industry

2nd out of 27 stocks

ILMN stock logo

About Illumina Stock (NASDAQ:ILMN)

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

ILMN Stock Price History

ILMN Stock News Headlines

Illumina's (ILMN) Overweight Rating Reaffirmed at Stephens
Obama’s DNC coup
As we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In fact, according to Tucker Carlson, in private even "Obama is telling people Biden can't win, and he is therefore in favor of an open convention."
Illumina (NASDAQ:ILMN) Stock Rating Upgraded by Citigroup
Stock Traders Buy High Volume of Illumina Put Options (NASDAQ:ILMN)
Illumina Sees Unusually Large Options Volume (NASDAQ:ILMN)
3 Biotech Stocks Turning DNA Dreams Into Dollars
Obama’s DNC coup
As we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In fact, according to Tucker Carlson, in private even "Obama is telling people Biden can't win, and he is therefore in favor of an open convention."
Illumina completes the divestiture of GRAIL
See More Headlines
Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/02/2024
Today
7/12/2024
Next Earnings (Confirmed)
8/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:ILMN
CUSIP
45232710
Employees
9,300
Year Founded
1998

Price Target and Rating

Average Stock Price Target
$158.57
High Stock Price Target
$242.00
Low Stock Price Target
$100.00
Potential Upside/Downside
+36.6%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
21 Analysts

Profitability

Net Income
$-1,161,000,000.00
Pretax Margin
-25.55%

Debt

Sales & Book Value

Annual Sales
$4.50 billion
Cash Flow
$3.68 per share
Book Value
$36.18 per share

Miscellaneous

Free Float
159,029,000
Market Cap
$18.49 billion
Optionable
Optionable
Beta
1.15

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Jacob Thaysen Ph.D.Mr. Jacob Thaysen Ph.D. (Age 49)
    CEO & Director
    Comp: $796.63k
  • Ms. Carissa L. Rollins (Age 54)
    Chief Information Officer
    Comp: $693.52k
  • Mr. Charles E. Dadswell Esq. (Age 65)
    Senior VP & General Counsel
    Comp: $1.03M
  • Dr. Joydeep Goswami M.B.A. (Age 53)
    Ph.D., Advisor
    Comp: $843.55k
  • Stephanie Campos
    President
  • Mr. Ankur Dhingra (Age 48)
    Chief Financial Officer
  • Mr. Kevin Carl Pegels (Age 56)
    Chief of Global Operations
  • Mr. Scott Ericksen (Age 51)
    VP & Chief Accounting Officer
  • Dr. Steven Barnard Ph.D.
    Chief Technology Officer
  • Ms. Sallilyn Schwartz
    Vice President of Investor Relations

Should I Buy Illumina Stock? ILMN Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Illumina, Inc.:

  • Illumina's stock price is currently at $109.22, potentially offering a good entry point for investors looking to buy at a lower price.
  • The company operates through Core Illumina and GRAIL segments, providing diversified revenue streams and exposure to different markets.
  • Illumina reported positive return on equity of 2.31% in the latest earnings results, indicating efficient use of shareholder funds.
  • Despite a negative net margin, Illumina's revenue for the quarter was $1.08 billion, surpassing analyst expectations and demonstrating strong sales performance.
  • With a market cap of $17.40 billion, Illumina is a well-established player in the genetic and genomic analysis industry, offering stability and potential for growth.

Cons

Investors should be bearish about investing in Illumina, Inc. for these reasons:

  • Analysts have issued mixed ratings on Illumina's stock, with two sell ratings, eleven hold ratings, and nine buy ratings, indicating uncertainty and differing opinions about the company's future performance.
  • The company's PE ratio of -13.40 may raise concerns among investors, as a negative PE ratio could suggest potential overvaluation or financial challenges.
  • Despite beating earnings estimates, Illumina's EPS of $0.09 for the quarter was only a slight improvement from the prior year, raising questions about the company's ability to significantly grow its profitability.
  • Evercore ISI lowered their price target on Illumina from $195.00 to $175.00, signaling a bearish outlook on the stock's potential future performance.
  • Barclays increased their target price on Illumina from $85.00 to $100.00 but gave the stock an "underweight" rating, suggesting concerns about the stock's valuation and growth prospects.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, July 7, 2024. Please send any questions or comments about these Illumina pros and cons to contact@marketbeat.com.

ILMN Stock Analysis - Frequently Asked Questions

How have ILMN shares performed this year?

Illumina's stock was trading at $139.24 at the start of the year. Since then, ILMN shares have decreased by 16.6% and is now trading at $116.09.
View the best growth stocks for 2024 here
.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) released its quarterly earnings results on Thursday, May, 2nd. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.05. The company's revenue for the quarter was down 1.0% on a year-over-year basis.
Read the conference call transcript
.

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Does Illumina have any subsidiaries?

The following companies are subsidiaries of Illumina: Grail, Enancio, BlueBee, Edico Genome, Conexio Genomics, GenoLogics, NextBio, and others.

Who are Illumina's major shareholders?

Top institutional shareholders of Illumina include Douglas Lane & Associates LLC (0.16%), DNB Asset Management AS (0.02%), SG Americas Securities LLC (0.01%) and Partnership Wealth Management LLC (0.01%). Insiders that own company stock include Susan H Tousi, Jacob Thaysen, Aimee L Hoyt, Charles Dadswell, Phillip G Febbo and Alexander Aravanis.
View institutional ownership trends
.

How do I buy shares of Illumina?

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL) and Salesforce (CRM).

This page (NASDAQ:ILMN) was last updated on 7/13/2024 by MarketBeat.com Staff

From Our Partners